Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
13 mars 2024 16h05 HE
|
Quoin Pharmaceuticals, Inc.
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical...
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
07 mars 2024 16h05 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering
05 mars 2024 08h00 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
04 mars 2024 08h00 HE
|
Quoin Pharmaceuticals, Inc.
Clearance to include teen patients in both the company’s open label and placebo controlled studies expected to significantly expand the number of eligible subjects, potentially expedite recruitment...
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product
08 févr. 2024 08h00 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company exclusively focused on the development and...
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
13 déc. 2023 08h30 HE
|
Quoin Pharmaceuticals, Inc.
Positive initial data and clean safety profile catalyze optimization planSize of both ongoing clinical trials significantly increasedLower dose eliminated from blinded trialDosing frequency changed to...
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results
08 nov. 2023 17h46 HE
|
Quoin Pharmaceuticals, Inc.
Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study Positive benefits were observed across a number of clinical...
Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET
03 nov. 2023 08h41 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...
REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
24 oct. 2023 09h32 HE
|
Quoin Pharmaceuticals, Inc.
Available Clinical Data from Six Subjects Demonstrates Well Defined Efficacy Signals Across a Number of Study Endpoints No Safety Concerns Observed in the Study to Date ASHBURN, Va., Oct. 24, 2023...
Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
24 oct. 2023 08h28 HE
|
Quoin Pharmaceuticals, Inc.
Available Clinical Data from Six Subjects Demonstrates Well Define Efficacy Signals Across a Number of Study Endpoints No Safety Concerns Observed in the Study to Date ASHBURN, Va., Oct. 24, 2023 ...